23andMe and mondoBIOTECH announced at Davos (the World Economic Forum in Switzerland) today that they will work together to further the study of rare diseases. According to the press release (below), mondoBIOTECH will identify individuals suffering from certain rare diseases and sponsor their enrollment in the 23andMe Personal Genome Service™. Researchers will use the information collected to learn more about the potential causes of these rare diseases.
CNBC Video:
Linda Avey appeared on CNBC this morning to discuss the company and the partnership – see “It’s All in the Genes.â€
The Press Release:
Davos, Switzerland – January 28th 2009 – 23andMe, Inc., an industry leader in personal genetics, and Mondobiotech AG, a Swiss research company dedicated to the development of treatments for rare diseases, today announced at the World Economic Forum in Davos, Switzerland, that they are collaborating to advance research of rare diseases.